|
🐬
|
Reshaping human antibodies for therapy
L. Riechmann,
M. Clark,
H. Waldmann,
G. Winter
|
10 |
1988 |
10
🐬
|
|
🐜
|
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.
25 auth.
B. Keymeulen,
E. Vandemeulebroucke,
A. Ziegler,
C. Mathieu,
L. Kaufman,
G. Hale,
F. Gorus,
M. Goldman,
M. Walter,
S. Candon,
L. Schandené,
L. Crenier,
C. D. De Block,
J. Seigneurin,
P. De Pauw,
...
D. Piérard,
I. Weets,
P. Rebello,
P. Bird,
E. Berrie,
M. Frewin,
H. Waldmann,
J. Bach,
D. Pipeleers,
L. Chatenoud
|
10 |
2005 |
10
🐜
|
|
🦁
|
Regulatory T cells in transplantation tolerance.
H. Waldmann,
L. Graça,
E. Adams,
P. Fairchild,
S. Cobbold
|
9 |
2005 |
9
🦁
|
|
🦁
|
Regulatory T cells in transplantation tolerance.
H. Waldmann,
L. Graça,
E. Adams,
P. Fairchild,
S. Cobbold
|
9 |
2005 |
9
🦁
|
|
🐜
|
Plasticity of Foxp3(+) T cells reflects promiscuous Foxp3 expression in conventional T cells but not reprogramming of regulatory T cells.
8 auth.
Takahisa Miyao,
S. Floess,
Ruka Setoguchi,
H. Luche,
H. Fehling,
H. Waldmann,
...
J. Huehn,
S. Hori
|
9 |
2012 |
9
🐜
|
|
🐬
|
Heterogeneity of natural Foxp3+ T cells: A committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity
N. Komatsu,
M. Mariotti-Ferrandiz,
Ying Wang,
B. Malissen,
H. Waldmann,
S. Hori
|
9 |
2009 |
9
🐬
|
|
🐜
|
Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).
12 auth.
J. Lundin,
E. Kimby,
M. Björkholm,
P. Broliden,
F. Celsing,
V. Hjalmar,
...
L. Möllgård,
P. Rebello,
G. Hale,
H. Waldmann,
H. Mellstedt,
A. Osterborg
|
9 |
2002 |
9
🐜
|
|
🐜
|
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.
21 auth.
Panagiotis D. Kottaridis,
D. Milligan,
R. Chopra,
R. Chakraverty,
S. Chakrabarti,
S. Robinson,
K. Peggs,
S. Verfuerth,
R. Pettengell,
J. Marsh,
...
S. Schey,
P. Mahendra,
G. Morgan,
G. Hale,
H. Waldmann,
M. de Elvira,
C. Williams,
S. Devereux,
D. Linch,
A. Goldstone,
S. Mackinnon
|
9 |
2000 |
9
🐜
|
|
🐜
|
The window of therapeutic opportunity in multiple sclerosis
11 auth.
A. Coles,
A. Cox,
E. Le Page,
Joanne L. Jones,
S. Trip,
J. Deans,
...
S. Seaman,
David H. Miller,
G. Hale,
H. Waldmann,
D. Compston
|
9 |
2005 |
9
🐜
|
|
🐜
|
Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis
9 auth.
A. Coles,
M. Wing,
P. Molyneux,
A. Paolillo,
C. Davie,
G. Hale,
...
David H. Miller,
H. Waldmann,
Alastair Compston
|
8 |
1999 |
8
🐜
|
|
🐢
|
The plasticity and stability of regulatory T cells
S. Sakaguchi,
D. Vignali,
A. Rudensky,
R. Niec,
H. Waldmann
|
8 |
2013 |
8
🐢
|
|
🐢
|
Induction of foxP3+ Regulatory T Cells in the Periphery of T Cell Receptor Transgenic Mice Tolerized to Transplants1
7 auth.
S. Cobbold,
R. Castejón,
E. Adams,
D. Zélénika,
L. Graça,
S. Humm,
...
H. Waldmann
|
8 |
2004 |
8
🐢
|
|
🐜
|
Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis
11 auth.
A. Coles,
M. Wing,
Sheila Smith,
F. Coraddu,
S. Greer,
C. Taylor,
...
A. Weetman,
G. Hale,
V. Chatterjee,
H. Waldmann,
A. Compston
|
8 |
1999 |
8
🐜
|
